Personalis, Inc. (PSNL)
Market Cap | 96.37M |
Revenue (ttm) | 68.68M |
Net Income (ttm) | -113.77M |
Shares Out | 46.78M |
EPS (ttm) | -2.46 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 405,483 |
Open | 1.96 |
Previous Close | 1.92 |
Day's Range | 1.95 - 2.07 |
52-Week Range | 1.73 - 5.58 |
Beta | 1.41 |
Analysts | Strong Buy |
Price Target | 7.00 (+239.81%) |
Earnings Date | May 3, 2023 |
About PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT D... [Read more]
Financial Performance
In 2022, Personalis's revenue was $65.05 million, a decrease of -23.92% compared to the previous year's $85.49 million. Losses were -$113.32 million, 73.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 239.81% from the latest price.
News

Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
FREMONT, Calif.--(BUSINESS WIRE)--Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023.

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
FREMONT, Calif. & KASHIWA, Japan & OSAKA, Japan--(BUSINESS WIRE)--Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer.

Personalis Reports First Quarter 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and...

Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, ABRCC, and Criterium announce major prospective clinical trial.

Personalis to Announce First Quarter 2023 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results o...

Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd An...

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
FREMONT, Calif. & LONDON--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK's Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announ...

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual...

Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Na...

Personalis Appoints Christopher Hall as Chief Executive Officer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as C...

Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended Dec...

Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 fina...

Personalis to Participate at Upcoming Investor Conferences
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor confe...

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenge...

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full ...

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the Compensation Committee of its Board of Directors granted, betwee...

Personalis Announces CEO Retirement and Transition
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of di...

Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
MENLO PARK, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based ...

Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34th Annual Piper Sandler...

Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
MENLO PARK, Calif.

Personalis Reports Third Quarter 2022 Financial Results
MENLO PARK, Calif.

Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
MENLO PARK, Calif.

Personalis to Announce Third Quarter 2022 Financial Results
MENLO PARK, Calif.

Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on a...

Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual ...